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The reverse transcriptase from human immunodeficiency virus 
type-I (HIV-RT) is a bifunctional enzyme, displaying DNA 
polymerase and ribonuclease H (RNase H) activities. In order 
to better characterize the molecular domains responsible for 
these activities, limited proteolysis on the 66 kilodalton 
form of HIV-RT (p66) was performed. The treatment of p66 with 
subtilisin-Carlsberg resulted in a characteristic breakdown 
pattern which depended upon the extent of proteolysis as well 
as the concentration of sodium dodecyl sulphate (SDS). The 
products of proteolysis (fragments) had apparent molecular 
masses of 51, 42, 33, 27, and 15 kilodaltons (kDa) as 
determined from SDS-polyacrylamide gel electrophoresis (SDS-
PAGE). Through Western blot analysis of the fragments, both 
the 51 and 42kDa fragments were found to be recognized by a 
monoclonal antibody (mAb) specific for a region near the C-
terminus of p66, while the 27 and 15kDa fragments were found 
to be recognized by a mAb specific for a region near the N-
terminus. In contrast, the 33kDa fragment was recognized by a 
mAb secific for a region in the middle of p66. It was proposed 
that HIV-RT, when denatured, is susceptible to proteolytic 
cleavage in at least two areas near the amino terminus. 
Cleavage at one site produces the C-terminal 51 and N-terminal 
15kDa fragments, while cleavage at the other site produces the 
C-terminal 42 and N-terminal 27kDa fragments. An RNase H 
activity gel analysis was performed with the fragments to 
determine if any of these fragments contained RNase H 
activity. Only the 51 and 42kDa fragments were found to 
contain RNase H activity. Attempts were also made, through 
dialysis, to renature the fragment mixture in solution for 
RNase H kinetic analysis. However, only very low levels of 
RNase H activity were observed with the fragment mixture. 
This study shows that proteolytic elimination of N-terminal 
portions of p66 results in C-terminal fragments which, under 
specific conditions, still demonstrate RNase H activity. These 
unique RNase H-active fragments may help elucidate mechanisms 
of RNase H catalysis, substrate binding, inhibition by RNase 
H specific inhibitors, and may aid in the determination of the 
crystal structure of the p66 RNase H domain. 
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CHAPTER I: INTRODUCTION 
Human immunodeficiency virus type-1 (HIV-1)1, a retrovirus, 
is known to be the causative agent of the acquired immune 
deficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983). All 
retrovirus particles contain a reverse transcriptase (RT) 
which is responsible for conversion of viral RNA into double-
stranded DNA provirus, which is then integrated into host DNA 
(Varmus and Swanstrom, 1984). Retroviral RT catalyzes several 
enzymatic reactions, including RNA- and DNA-directed DNA 
polymerization as well as hydrolysis of the RNA component of 
RNA-DNA hybrids (Varmus and Swanstrom, 1984). The latter 
activity is referred to as ribonuclease H (RNase H) . The 
function of the RNase H in retroviruses is not well defined, 
however, several functions have been suggested. It has been 
shown that, with the avian sarcoma virus reverse transcriptase 
associated RNase H, the RNase H is capable of not only 
generating oligomeric RNA primers for plus-strand DNA 
synthesis, but also removing RNA primers of both minus- and 
plus-strand DNA (Omer and Faras, 1982; Resnick et al., 1984;). 
Furthermore, it has been shown that both the DNA polymerase 
and RNase H activities of the reverse transcriptase enzyme 
from human immunodeficiency virus (Hansen et al., 1988; 
Starnes and Cheng, 1989; Mizrahi et al., 1989), avian 
myeloblastosis virus (Grandgenett et al., 1973), and murine 
lekemia virus (Moelling, 1974) reside on a single polypeptide. 
Studies with HIV-RT have shown that the RNase H activity is 
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associated with the carboxy terminus of the protein (Johnson 
et al., 1986; Tisdale et al., 1989; Hansen et al., 1988) and 
the DNA polymerase activity with the amino terminus (Johnson 
et al., 1986; Starnes and Cheng, 1989; Tisdale et al., 1988; 
Mizrahi et al., 1989). 
The HIV-RT gene encodes a 66kDa protein. However, two 
reverse transcriptase polypeptides, with apparent molecular 
masses of 66 and 51kDa, have been isolated from HIV virions 
(Di Marzo Veronese et al., 1986). While both share the same 
amino termini, the larger form has an additional stretch of 
amino acids present in the carboxy terminus (Lightfoot et al., 
1986) . In vitro, the 66kDa protein (p66), alone, exists as a 
homodimer, whereas an equal mixture of p66 and the 51kDa 
protein (p51) exists as a p66/p51 heterodimer (Lowe, et al., 
1988) . In vivo, p66 is thought to be processed to p51 by 
cleavage of a 15kDa, C-terminal portion of p66 (Di Marzo 
Veronese et al., 1986; Lightfoote et al., 1986; Ferris et al., 
1990). It is not known for sure whether the endogenous HIV-RT 
exists as a homodimer, heterodimer, or p66 monomer. 
Homogeneous preparations of the p66 have been prepared by 
cloning in E. coli (Hizi et al., 1988; Larder et al., 1987). 
The p66 has been shown to contain RNA-and DNA-directed DNA 
polymerase activities (Starnes et al., 1988) as well as an 
RNase H activity (Starnes and Cheng, 1989). While low levels 
of DNA polymerase activity have been observed with the p51 
form (Starnes and Cheng, 1989; Tisdale et al., 1988), this 
3 
form contains no detectable RNase H activity (Mizrahi et al., 
1989; Tisdale et al., 1989). 
The HIV-RT is essential for virus replication. Without this 
enzyme, the HIV genome could not be replicated, and thus, 
could not be expressed. Because of the crucial role of the 
HIV-RT in virus replication, this enzyme is an important 
target for AIDS chemotherapy. Several compounds have been 
tested for their ability to inhibit HIV replication. Most of 
these compounds are nucleoside analogues. So far, the most 
promising compound is the thymidine analogue, 3'-azido-3'-
deoxythymidine (AZT). THe structure of AZT is essentially 
identical to that of thymidine, with the exception that the 
3'-hydroxy1 group of thymidine is replaced by an azido (Nj) 
group. AZT has been shown to be a potent inhibitor of HIV 
replication in vitro (Mitsuya et al., 1985). Furthermore, AZT 
has been shown to not only significantly improve the condition 
of AIDS patients, but also increase their survival rates 
(Fischl et al., 1987). The proposed mechanism of action of AZT 
involves both inhibition of the HIV-RT and termination of the 
viral DNA chain (Langtry and Campoli-Richards, 1989). Before 
AZT can be active, however, it must be converted to the 5'-
triphosphate form. This phosphorylation is performed by 
cellular kinases (Furman et al., 1986). AZT-triphosphate has 
been shown to competitively inhibit the binding of thymidine-
triphosphate to HIV-RT (St. Clair et al. , 1987). Once AZT-
triphosphate has become bound to HIV-RT, a DNA chain 
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elongation reaction occurs in which AZT-monophosphate is 
incorporated into the DNA chain, accompanied by the release of 
pyrophosphate. It has been shown that, following AZT 
incorporation, DNA chain elongation is terminated because AZT 
is lacking the 3'-hydroxy1 group which is essential for chain 
elongation (St. Clair et al., 1987). Studies, such as these, 
demonstrate the importance of HIV-RT as a target for AIDS 
chemotherapy. Although most HIV-RT inhibitors (such as AZT) 
are targeted to the reverse transcriptase activity of HIV-RT, 
it has been suggested that the RNase H activity of HIV-RT may 
also be a possible target for inhibition of HIV replication 
(Starnes and Cheng, 1989). 
In several studies, limited proteolysis has been used to 
physically separate two or more enzymatic activities that are 
contained within the same polypeptide. Such studies have been 
performed with both retroviral and non-retroviral DNA 
polymerases. The alpha subunit of avian myeloblastosis virus 
RT has been shown to contain both DNA polymerase and RNase H 
activities (Grandgnett et al., 1973). Limited proteolysis of 
this RT with chymotrypsin showed that the enzyme could be 
broken down into a number of polypeptide fragments, one of 
which contained RNase K activity (Lai and Verma, 1978). 
However, under the conditions used, a fragment containing only 
DNA polymerase activity was not isolated. Furthermore, 
limited proteolysis of E. coli DNA polymerase I with 
subtilisin results in the production of the Klenow fragment 
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which contains DNA polymerase activity and 3'-5'exonuclease 
(degradative) activity but is devoid of 5'-3' exonuclease 
activity (Klenow and Overgaard-Hansen, 1970; Brutlag et al., 
1969). Under the conditions used, the polymerase activity of 
the fragment was significantly greater than that of the intact 
enzyme. 
Domain specific studies such as these are important in the 
physical characterization of enzymes and may be important in 
the development of inhibitors of enzymes from pathogens. Such 
analyses may answer questions pertaining to the number and 
arrangement of functional sites present on these enzymes and 
the effect of conformational changes (via proteolytic 
cleavage) on enzyme activity. In the work reported here, the 
SDS-dependent proteolysis of HIV-RT by subtilisin was examined 
and the cleavage fragments containing RNase H activity were 
identified. 
Due to the significance of the HIV-RT as a target for AIDS 
chemotherapy, there is a need to further develope HIV-RT 
inhibitors of not only the reverse transcriptase domain, but 
also the RNase H domain. However, this development will depend 
upon a better understanding of these two domains. The purpose 
of this research was to further characterize these two domains 
with the view that the results obtained might facilitate the 
development of HIV-RT targeted AIDS chemotherapy. Initially, 
the goal of this research was to physically separate the 
reverse transcriptase domain from the RNase H domain of HIV-RT 
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by proteolytically cutting the enzyme at the domain interface. 
Under the proteolysis conditions used in this research, 
however, it was shown that, rather than cutting between the 
two domains, cuts were made near the amino terminus of HIV-RT 
(in the reverse transcriptase domain). However, these cuts 
resulted in the generation of carboxy terminal fragments which 
still contained RNase H activity. The new goal of this 
research was then to identify these RNase H active fragments 
and examine the proteolysis reaction which produced them. 
CHAPTER TWO: 
MATERIALS AND METHODS 
Materials 
Recombinant p66 and p66 specific monoclonal antibodies (mAb) 
were kindly provided by Dr. Stephen H. Hughes (National Cancer 
Institute, Frederick, MD). The cloning, expression, and 
purification of p66 have been described (Hizi et al., 1988; 
Clark et al., 1990) as has the production and mapping of the 
mAb's (Ferris et al., 1990). The recombinant p66/p51 
heterodimer was provided by Burroughs Wellcome Company. 
Subtilisin Carlsberg, guanosine 5'-triphosphate, 
phenylmethylsulfonyl fluoride (PMSF) , and alkaline phosphatase 
conjugated goat anti-mouse IgG were purchased from Sigma 
Chemical Company. The alkaline phosphatase chromagenic 
substrates, 5-bromo-4-chloro-3-indolylphosphate p-Toluidine 
Salt (BCIP) and nitroblue tetrazolium chloride (NBT), were 
purchased from Bethesda Research Laboratory. RNA polymerase 
and Ribonuclease H, both from E. coli, were purchased from 
Pharmacia LKB Biotechnology. The [a-^P]GTP and [^H]GTP were 
purchased from Dupont New England Nuclear. Materials for 
polyacrylamide gel silver staining were purchased from Sigma 
Chemical Company (kit AG-5 or AG-25). All other materials were 
reagent grade or better. 
Limited Proteolysis 
Reaction mixtures (llOvil) contained 86mM sodium phosphate 
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buffer, pH 6.5, 8.6mM 2-mercaptoethanol, 5yg of p66 or p66/p51 
(as indicated), 0.05ug subtilisin (11.3 Units/mg) and SDS as 
indicated. Phosphate buffer containing 2-mercaptoethanol and 
SDS were prewarmed to 37°C, then p66 was added. This mixture 
was incubated at 37°C for another minute and proteolysis was 
initiated by the addition of subtilisin. These reactions 
proceeded at 37°C for the indicated times and were terminated 
by adding phenylmethylsulfonyl fluoride (PMSF) to a final 
concentration of 2.4mM. 
Termination of proteolysis 
Two different compounds were tested for their ability to 
terminate subtilisin mediated proteolysis. These compounds 
were PMSF and Indole. 
PMSF- Standard cleavage reaction mixtures were prepared as 
described above, except 5yg of BSA was used as the protease 
substrate instead of p66. Prior to subtilisin addition, PMSF 
was added to final concentrations of 0.001, 0.1, 1, and lOmM. 
Subtilisin was then added and samples were incubated for 5 min 
at 37°C and analyzed by SDS-PAGE. 
Indole- The procedure was the same as described for the PMSF 
termination, except Indole, instead of PMSF, was added prior 
to subtilisin addition. 
SDS-polyacrylamide gel electrophoresis 
Polyacrylamide gels, 12.5 or 10%, were prepared as 
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previously described (Laemmli, 1970). Proteolysis reaction 
mixtures were diluted in SDS-solubilization buffer (62.5mM 
Tris-HCl, pH6.8, 5% glycerol, 1% SDS, 50mM 2-mercaptoethanol, 
and 0.025% bromophenol blue) and boiled for 5 min. 
Approximately 0.7ug total protein from either cleavage 
reactions or control (without protease) reaction mixtures were 
loaded onto the gel. Low molecular weight standards (BIORAD) 
were run with each gel. These standards have molecular masses 
of 97.4 (phosphorylase b), 66.2 (bovine serum albumin), 45.0 
(ovalbumin), 31.0 (carbonic ahydrase), 21.5 (soybean trypsin 
inhibitor), and 14.4kDa (lysozyme). All samples were 
electrophoresed at 50mA constant current for approximately two 
hours. Proteins in gels were silver-stained using the silver 
stain kit (number AG-25) purchased from Sigma Chemical 
Company. 
Western blotting and Immunostaining 
Following SDS-PAGE, solubilized cleavage reaction samples 
were electroblotted to nitrocellulose paper as previously 
described (Judd, 1988).Immediately following electrophoresis, 
the appropriate gel lanes were cut from the gel and overlaid 
with strips of nitrocellulose paper (NCP). Proteins were 
electroblotted from the gel to NCP at 0.6 A, 20 V for 16 h in 
20mM dibasic sodium phosphate. After electroblotting, the NCP 
strips were blocked for 1 h with 0.05% Tween-20 in Dulbecco's 
phosphate buffered saline (DPBS/tween) (Batteiger et al., 
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1982), followed by incubation with a 1:50 to 1:400 dilution of 
the appropriate mAb (Ferris et al., 1990) for 16 to 24 h. The 
NCP strips were then washed for 2 h in 2 changes of 
DPBS/Tween, to remove unbound mAb. This was followed by 
incubation of the NCP strip for 1 h with lpg of alkaline 
phosphatase conjugated goat anti-mouse IgG. After this, strips 
were washed for 1 h in 2 changes of DPBS/Tween to remove 
unbound IgG. Following this, strips were washed for 15 min in 
the alkaline phosphatase reaction buffer (0.1M Tris-HCl, pH 
9.5, 0.1M NaCl, and 50mM MgClj), then incubated in 20ml of the 
above buffer containing the NBT (88pl) and BCIP (66yl) 
alkaline phosphatase substrates. Alkaline phosphatase activity 
was observed by the appearance of purple bands on NCP strips 
and the reaction was terminated by transfer of the NCP to tap 
water. 
RNase H Substrate Preparation 
Poly(dC)'[a-^P]poly(rG)- This substrate was used for the 
RNase H activity gel analysis and was prepared as already 
described (Starnes and Cheng, 1989). The reaction mixtures 
(50yil) contained 50mM Tris-HCl,pH 7.8, lOOmM KC1, 5mM MgC^, 
ImM MnCl2, 5mM dithiothreitol (DTT) , 5% glycerol, 0.2 Aj^q units 
of poly(dC) and 500pM [a-^P]GTP (10 Ci/mmol) . This mixture was 
warmed to 37°C and hybrid synthesis was initiated with 40U of 
E. coli RNA polymerase. The reaction proceded for 10 min and 
was terminated by addition of EDTA to a final concentration of 
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83mM. The hybrid was separated from unreacted GTP by 
chromatography on a 1.5 ml Sephadex G-50 column. Void volume 
fractions were pooled and extracted once with an equal volume 
of phenol/chloroform/isoamyl alcohol (1:1:0.04). The aqueous 
phase was precipitated with two volumes of 100% ethanol and 
the precipitate, containing the hybrid, was resuspended in 
sterile water. 
Poly (dC) • [^H] poly (rG)- This substrate was used in the 
solution assay for RNase H and was prepared as described above 
except the reaction volume was 1ml and contained 4 A2go units 
of poly(dC) and 500jiM [^H]GTP (0.5 Ci/mmol). The hybrid was 
separated from free nucleotides by chromatography on Sephadex 
G-50 (9 ml column). 
RNase H activity gel 
The RNase H activity gel was prepared as previously described 
(Starnes and Cheng, 1989). A 10% polyacrylamide gel was 
prepared as described above, except that 10^ cpm of 
poly (dC) • [32P]poly (rG) was added to the running gel mixture 
prior to polymerization. Samples to be analyzed on these gels 
(40jil) , were solubilized by incubation of the protein mixtures 
at 37°C for 5 min in a buffer containing 50mM Tris-HCl, pH7.5, 
5% glycerol, 2mM EDTA, 1% SDS, lmg/ml nuclease free bovine 
serum albumin (BSA), and 0.5mM 2-mercaptoethanol. 
Electrophoresis was performed at room temperature for 3 h at 
30 mA constant current. After electrophoresis, proteins were 
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renatured as already described (Starnes and Cheng, 1989) . This 
involved washing the gel by shaking at room temperature for 1 
h in 2 changes (1 liter) of 50 mM Tris-HCl, pH 8.0, 2mM DTT, 
20% glycerol, followed by washing for 16 h in 2 changes (1 
liter) of the above buffer also containing 50mM KC1 and 8mM 
MgCl2. The gel was then washed for another 8 h in 2 changes (1 
liter) of the same buffer without glycerol. For the RNase H 
reaction, the gel was incubated for 20 h at 37° in the same 
buffer without shaking. This was followed by washing (with 
shaking) at 4°C for 4h in 4 (1 liter) changes of cold 5% 
trichloroacetic acid, lOmM pyrophosphate, followed by 30 min 
at room temperature in 5% glycerol. The gel was dried under 
vacuum and autoradiography was performed using Kodak X-OMAT AR 
film. 
Protein renaturation and solution RNase H analysis 
Renaturation- These experiments were performed with 
preparations which had undergone proteolysis in 0.95% SDS for 
50 s. Four attempts were made to renature the polypeptides in 
the reaction mixtures. In the first attempt to renature the 
polypeptides, following PMSF termination, guanidine 
hydrochloride was added to the reaction mixtures, to a final 
concentration of 3M. These mixtures were then incubated for 2 
h at 37°C and transferred to prewashed (see below) dialysis 
tubing (molecular weight cut off 3500). Samples were then 
dialyzed (with shaking) at room temperature for 24 h in 4, 1 
13 
liter changes of a renaturation buffer which consisted of 50mM 
Tris-HCl, pH 8.0, 20% glycerol, and 2mM DTT. This was followed 
by dialysis for 3 h in 1 liter of the above buffer with 50mM 
KC1, followed by dialysis for 14 h in 2, 1 liter changes of 
the same buffer without KC1. Samples were then put on ice for 
1 h and 15pl aliquots were taken and assayed for RNase H 
activity using the solution RNase H assay procedure (below). 
Nuclease free BSA was then added (40pg/ml) to the mixtures, 
which were then concentrated by ultrafiltration, using a 
Centricon-3 microconcentration apparattus (molecular weight 
cut off 3000) (Amicon). This involved centrifugation of the 
samples at 5000 x g for 6 h at 0°C. Aliquots (15ul) of each 
concentrated sample were then assayed for RNase H activity. 
In the second trial, samples were transferred, immediately 
after PMSF termination, to dialysis tubing (3500 molecular 
weight cut off) and dialyzed (with shaking) at room 
temperature for 40 h in 8, 1 liter changes of a renaturation 
buffer consisting of 50mM Tris-HCl, pH 8.0, 20% glycerol, and 
2mM DTT. Samples were put on ice for 1 h, then 15]il aliquots 
were assayed for RNase H activity. The remainder of the 
samples were then concentrated by ultrafiltration as described 
in trial one. An aliquot (15ul) of each concentrated sample 
was then assayed for RNase H activity. 
In the third attempt to renature the fragments, the 
procedure was essentially identical to that used in the first 
attempt, however, the renaturation buffer also contained ImM 
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PMSF, which was added to inhibit any subtilisin which 
renatured with the p66 cleavage fragments. 
In the fourth and final attempt, immediately after 
termination of proteolysis, cleavage or control reaction 
mixtures (113pl, see methods) were added to 1200)il of ice cold 
BSA (20mg/ml) . Samples were then dialyzed with the 
renaturation buffer described in the second trial, and 
concentrated (4 h centrifugation at room temperature) as 
described above. 15yl aliquots of concentrated dialyzed 
samples were assayed for RNase H activity. 
The dialysis tubing used in the four above renaturation 
procedures was prepared by heating the tubing at 80°C for 1 h 
in a buffer containing 5.4mM Na,EDTA, 14.0mM NaHCOp and 7.OmM 
2-mercaptoethanol. This was followed by rinsing the tubing 
overnight in dHjO. 
Solution RNase H assays- Conditions for assays were 
identical to those described by Starns and Cheng (1989). 
Reaction mixtures (50ul) contained 50mM Tris-HCl, pH 8.0, 2mM 
DTT, lOOpg/ml nuclease free BSA, 50mM KC1, 8mM MgC^, and 1.5 
x 105 cpm of ^H-labeled substrate (poly (dC) • [3H}poly (rG) ) . 
Reactions were initiated with 15ul of dialyzed cleavage or 
control samples and incubated at 37°C for 2 h. Reactions were 
terminated by transfer to ice followed by addition of 50]il of 
ice cold 7% perchloric acid. After 30 min on ice, precipitates 
(poly (dC )• [-H] poly (rG) ) were pelleted by centrifugation at 
15 
10,000 rpm (Savant, model HSC10K) for 15 min. An aliquot 
(75yil) of each supernatant was added to 5 ml of scintillation 
mixture which was then counted for raioactivity. One unit of 
RNase H is defined as the amount of enzyme which produces 1 
nmol of acid-soluble ribonucleotide/h at 37°C. 
CHAPTER III: 
Results 
Limited Proteolysis of p66- In preliminary experiments 
(see SDS-requirement below) it was observed that, under the 
reaction conditions used, proteolysis of p66 by subtilisin 
required SDS. Here, p66 was treated with subtilisin in the 
presence of SDS, and both the reaction time and the 
concentration of SDS were varied. As shown by SDS-PAGE (fig. 
1A) , no significant proteolysis occurred unless SDS was 
present. However, in 0.095% or 0.95% SDS, subtilisin produced 
several distinct polypeptide fragments. In a 25 s reaction 
with either concentration of SDS, fragments with apparent 
molecular masses of 51, 42, 33, 27, and 15kDa were generated 
(lanes 7 and 8) . The breakdown patterns were essentially 
identical when proteolysis took place for 25 s in 0.95% (lane 
7) and 0.095% SDS (lane 8). However, the intensity of the 
33kDa cleavage fragment was much less from the 0.95% SDS 
reaction than that from the 0.095% SDS reaction. A less 
intense 40kDa band was also observed in lane 8, but was not 
readily detectable in lane 7. Intact p66 was still present in 
both reactions as seen from the 66kDa band in lanes 7 and 8. 
When cleavage reactions were run for 70 s, the breakdown 
products were similar to those of the 25 s reactions, except, 
p66 was almost completely degraded in reactions containing 
0.095% SDS (lane 5). Extensive proteolysis was observed in the 








Figure 1A: Silver stained gel of SDS-PAGE analysis of p66 
digestions. Proteolysis was performed for different time 
intervals in the presence or absence of SDS. Terminated 
reaction mixtures were solubilized in SDS sample buffer and 
0.7yg total protein was loaded onto each lane. The major 
breakdown fragments are shown by arrows in lane 8. Lanes: 1, 
5 min digestion in 0.95% SDS; 2, 5 min digestion in 0.095% 
SDS; 3, 5 min digestion without SDS; 4, 70 s digestion in 
0.95% SDS; 5, 70 s digestion in 0.095% SDS; 6, 70 s digestion 
without SDS; 7, 25 s digestion in 0.95% SDS; 8, 25 s digestion 
in 0.095% SDS; 9, 25 s digestion without SDS; 10, molecular 
weight markers. 
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2 respectively). After these treatments, neither p66 nor the 
51kDa polypeptide were detected. The 0.095% SDS reaction 
showed a faint 42kDa band whereas the same band in the 0.95% 
SDS reaction was clearly visible. Both reactions generated 
strong 33 and 15kDa bands, as well as a number of less intense 
bands between the 33 and 15kDa bands. Even after 5 min, there 
was no significant proteolysis of p66 in reactions without SDS 
(lane 3). 
In order to further define the generation of these cleavage 
fragments, 0.95% SDS proteolysis reactions were carried out 
with shorter reaction times, and again visualized by SDS-PAGE 
(fig. IB). In 30 s, 20 s, and 15 s cleavage reactions (lanes 
2-4, respectively), all five of the above breakdown products 
were generated. In contrast, the 10 s cleavage reaction (lane 
5) contained all of the breakdown products except the 33kDa 
fragment, suggesting that this fragment may be generated by 
further proteolysis of the 51 or 42kDa fragment. 
SDS-requirement- In preliminary experiments, proteolysis of 
p66 by subtilisin was assumed to be stopped by addition of 
SDS-sample buffer followed by boiling. Later, it was found 
that proteolysis did not actually start until the SDS-sample 
buffer was added. To show that this was true, two identical 
p66, 5 min cleavage reactions were set up as described (see 
methods), except SDS was not present in the reaction mixtures. 
One cleavage reaction was terminated by adding PMSF (see 
below) to a final concentration of 2mM followed by 
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Figure IB: Silver stained gel from shorter duration p66 
proteolysis reactions. Proteolysis was performed in 0.95% SDS 
for the indicated times. The cleavage fragments are shown by 
arrows. Lanes: 1, p66 control; 2, 30 s cleavage reaction; 3, 
20 s reaction; 4, 15 s reaction; 5, 10 s reaction; 6, 
molecular weight markers. 
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solubilization with SDS-sample buffer and boiling. The other 
reaction was terminated with only SDS-sample buffer followed 
by boiling. Aliquots of each reaction mixture were analyzed by 
SDS-PAGE (fig. 2). The reaction terminated with PMSF (lane 3) 
showed only minor proteolysis as compared to the single 66kDa 
band seen in the p66 control reaction (lane 1). In contrast, 
the reaction terminated with SDS-sample buffer (lane 2) 
contained the 5 breakdown products which have already been 
described suggesting that something in the SDS-sample buffer 
was facilitating proteolysis. SDS seemed to be the most likely 
component. To show that SDS was responsible for the observed 
proteolysis, digestion of p66 with subtilisin was performed 
both in the presence or absence of SDS. Two concentrations of 
SDS were used, 0.95% (approximately the same as that present 
in the SDS-sample buffer) and 0.095% (a 10 fold decrease of 
that present in the SDS-sample buffer). The results of this 
experiment have already been discussed above (fig. 1A) in 
which it was confirmed that, under the conditions used, SDS 
was essential for proteolysis to take place. 
Termination- Two different compounds were separately tested 
for their ability to terminate proteolysis. The two compounds 
chosen were PMSF and Indole. Indole was chosen because it is 
known to be a potent competitive inhibitor of subtilisin 
(Smith et al., 1966). PMSF was also chosen because it has been 
used by others to terminate proteolytic reactions mediated by 
serine proteases (Lai and Verma, 1978) . Due to a limited 
21 
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Figure 2: Silver stained gel showing the SDS requirement of 
subtilisin. Proteolysis of p66 was performed for 5 min and 
reactions were terminated with SDS-sample buffer or PMSF. 
Lanes: 1, p66 control; 2, cleavage reaction terminated with 
SDS-sample buffer; 3, cleavage reaction terminated with PMSF; 
4, molecular weight markers. 
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availability of p66, BSA was used as the protease substrate in 
these experiments instead of p66. In order to insure that 
these compounds would inhibit proteolysis, either PMSF or 
Indole was added to the reaction mixtures prior to the 
addition of subtilisin. As shown by SDS-PAGE analysis of the 
PMSF terminations (fig. 3A), when PMSF was added to final 
concentrations of 0.1, 1, and lOmM (lanes 4-6, respectively), 
no proteolysis was observed when compared to the BSA control 
sample (lane 1), which contained no subtilisin. In contrast, 
when PMSF was only present at concentrations of 0.001 and 
O.OlmM (lanes 2 and 3), proteolysis was observed as seen by 
the breakdown bands which were not present in the BSA control 
sample. In reactions which contained no PMSF, a ladder of 
breakdown products was generated (lanes 7 and 8) , which was 
similar to the breakdown seen in the 0.001 and O.OlmM PMSF 
reactions. It should be noted, however, that the 0.1, 1, and 
lOmM reactions (lanes 4-6) only contained one 66.2kDa BSA 
band, whereas the BSA control reaction (lane 1) contained 
several bands. This was more than likely due to incomplete 
silver staining in lanes 4-6, however, the results still 
clearly indicate that there is no significant proteolysis 
occuring in these reactions. 
In contrast to the above results, it was found that Indole, 
at the concentrations used, was not an effective terminator of 

















Figure 3: Silver stained gels of PMSF (A) and Indole (B) 
termination reactions. BSA was treated with subtilisin for 5 
min in the presence of PMSF or Indole at the indicated 
concentrations. (A) PMSF termination; Lanes: 1, BSA control; 
2, O.OOlmM PMSF; 3, O.OlmM PMSF; 4, O.lmM PMSF; 5, l.OmM PMSF; 
6, lOmM PMSF; 7 and 8, contained no PMSF; 9, molecular weight 
markers. (B) Indole termination; Lanes: 1, BSA control; 2, 
O.OOlmM Indole; 3, O.OlmM Indole; 4, O.lmM Indole; 5, l.OmM 
Indole; 6, lOmM Indole; 7, no Indole; 8, molecular weight 
markers. 
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the Indole termination reactions (fig. 3B) showed that when 
Indole was present during protolysis at concentrations of 
0.001, 0.01, 0.1, 1, and lOmM, proteolysis of BSA was observed 
(lanes 2-6) when compared to the BSA control sample (lane 1). 
In proteolysis reactions which contained no Indole (lane 7), 
the observed breakdown was identical to that seen when Indole 
was present at the above concentrations. After analyzing the 
abilities of PMSF and Indole to terminate proteolysis by 
subtilisin, it was evident that only PMSF effectively stops 
the proteolysis of BSA by subtilisin. Because of this, PMSF 
was chosen to terminate the subtilisin digestion of p66. 
Localization of Fragments- In order to determine the 
approximate location of the cleavage fragments within p66, the 
fragments were mapped by Western blotting with mAb's specific 
for defined regions of the HIV-RT (Ferris et al., 1990) (fig. 
4A) . The 51 and 42kDa fragments, along with p66, were 
recognized by mAb-50 which is specific for a region near the 
C-terminus of HIV-RT (fig. 4B). The fragments were also 
probed with mAb-42, which is specific for a region near the N-
terminus. The 51, 27, and 15kDa fragments, along with intact 
p66, were recognized by this mAb (fig. 4D) . In contrast, none 
of the fragments were recognized by mAb-19, which is specific 
for a smaller region on p66 near the N-terminus (fig. 4C) . 
Only p66 was recognized by mAb-19. The 33kDa fragment, along 
with the 51, 42, and 40kDa fragments, was recognized by mAb-
21, which is specific for a region in the middle of p66 (fig. 
HjN. 
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Figure 4: Western blot analysis of p66 breakdown fragments. 
Solubilized cleavage reaction mixtures(0.7vig total protein) 
and control mixtures(0.7pg intact p66) were subjected to SDS-
PAGE followed by protein transfer to nitrocellulose paper. 
Transfers were probed with mAb's and binding was observed by 
alkaline phosphatase reaction.(A) A map showing p66 binding 
regions of mab-19, mAb-42, mAb-21, and mAb-50. (B) mAb-50 blot 
containing cleavage(CLV) or control(CT) samples. (C) mAb-19 
blot. (D) mAb-42 blot. <E) mAb-21 blot. 
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4E) . The 33kDa fragment was not recognized by mAb's specific 
for the N or C terminus (mAb-42 and mAb-50, respectively). 
These data indicated that the 51 and 42kDa fragments are 
associated with the C-terminus, the 27 and 15kDa fragments 
with the N-terminus, and the 33kDa fragment with a central 
portion of p66. 
Antibody titration- Prior to the above blotting experiments, 
it was first necessary to determine the appropriate mAb 
concentrations to be used for probing the fragments. This was 
done in order to insure that recognition of cleavage fragments 
by p66 specific mAb's was a result of specific binding of the 
mAb's to defined regions on p66 rather than to non-specific 
binding. This was performed by Western blotting of NCP strips 
with SDS-PAGE protein standards side by side with the cleavage 
fragments. Since the mAb's were specific for only p66, or 
defined regions of p66, any binding of the mAb's to the 
protein standards would be non-specific. The concentrations of 
the primary (mAb) and secondary (IgG) antibodies were both 
varied. Initially, mAb-50 blots were probed with 1:50, 1:100, 
1:200, and 1:400 dilutions of mAb-50 followed by 20yg of the 
IgG conjugate (fig. 5A). When blots were probed with a 1:50 
dilution (lanes 1 and 2), three of the protein standards 
(97.4, 66.2, and 21.5kDa) (lane 2), most noticeably the 
21.5kDa standard (Soybean trypsin inhibitor), were bound by 
mAb-50, indicating that non-specific binding was occurring. 
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Figure 5A: mAb-50 probed Western blots of p66 cleavage 
fragments and protein standards. Cleavage fragments and 
protein standards were electroblotted from the polyacrylamide 
gel and probed with the indicated mAb-50 dilutions. Lanes: 1, 
cleavage fragments probed with 1:50 mAb-50 dilution; 2, 
protein standards probed with 1:50 mAb-50 dilution; 3, 
cleavage fragments probed with 1:100 dilution; 4, protein 
standards probed with 1:100 dilution; 5, cleavage fragments 
probed with 1:200 dilution; 6, protein standards probed with 
1:200 dilution; 7, cleavage fragments probed with 1:400 
dilution; 8, protein standards probed with 1:400 dilution. 
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4), 1:200 (lane 6), and 1:400 dilutions (lane 8). As a result 
of this non-specific binding, the observed mAb-50 recognition 
of the cleavage fragments (51 and 42kDa) in these blots (odd 
numbered lanes) was not valid. The non-specific binding still 
present in blotting with the 1:400 dilution of mAb-50 
suggested that the IgG (secondary antibody) might be the cause 
of this non-specific binding. Another set of blots were run 
again with the fragments and standards, side by side. This 
time, however, the dilution of mAb-50 remained constant 
(1:100), while the amount of IgG was varied (fig. 5B) . Two 
different amounts of IgG were used, 5 and 2.5ug. Although non­
specific binding of the standards (97.4, 66.0, and 21.5) was 
observed in the 5yig IgG blot (lane 2) , nonspecific binding to 
standards was negligible in the 2.5 yg IgG blot (lane 4). 
These results established that binding of mAb-50 to the 
fragments (lanes 1 and 3) was specific. The appropriate 
conditions for Western blotting with mAb-50 therefore were 
found to to be a 1:100 dilution of mAb-50, followed by a 
maximum of 2.5jjg IgG. Similar antibody titration experiments 
were run with the other mAb's used. The results were similar 
to the mAb-50 results, and it was determined that a minimum 
1:100 dilution of each of these mAb's followed by a maximum of 
2.5yg of IgG were appropriate Western Blotting conditions for 
these antibodies. 
RNase H Activity of Fragments- An RNase H activity gel 





Figure 5B: Western blots of p66 cleavage fragments and protein 
standards probed with a 1:100 dilution of mAb-50, followed by 
incubation with the indicated amounts of IgG. Lanes: 1, 
cleavage fragments incubated with 5 yg of IgG; 2, protein 
standards incubated with 5pg IgG; 3, cleavage fragments 
incubated with 2.5yg of IgG; 4, protein standards incubated 
with 2.5yg IgG. 
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fragments retained RNase H activity. Results of this analysis 
are shown in Figure 6A. Proteolysis of p66 generated two 
fragments with RNase H activity (lane 3). The apparent 
molecular masses of the fragments associated with these 
regions of activity (windows) were determined to be 51 and 
42kDa. The first molecular mass determination of these windows 
yielded high apparent molecular masses of 57 and 46kDa for the 
51 and 42kDa fragments, respectively. However, these were 
later determined (see below) to be from the 51 and 42kDa 
fragments respectively. As expected, a window in this lane 
corresponding to undigested p66 was not observed since p66 was 
completely degraded as seen by SDS-PAGE analysis of this 
reaction (fig. 6B). Unexpectedly, there was no window of RNase 
H activity observed with the p66 control reaction (lane 2) . 
Activity windows with p66 have been observed when larger 
amounts (10U RNase H) are used (fig. 6C, lane 2). However, 
when this amount of intact p66 was analyzed in the gel assay, 
an intense 51kDa window was also observed. A faint 51kDa band 
was also observed in the SDS-PAGE analysis of this same sample 
(fig. 6D lane 1). Since this sample contained no subtilisin, 
the observed breakdown was not due to subtilisin proteolysis. 
The source of this breakdown is not known. 
Due to the high molecular masses, 57 and 46kDa, associated 
with the two regions of activity in the gel assay, it was 
necessary to confirm that these observed windows were 
generated by the 51 and 42kDa fragments and not from fragment 
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Figure 6A: Autoradiogram of RNase H activity gel analysis of 
RNase H enzymes and cleavage fragments. The gel was run as 
described under Materials and Methods. Lanes: 1, E. coli RNase 
H (10 Units); 2, HIV-RT control (1.5yg p66 (3 Units RNase H, 
initially)); 3, cleavage reaction mixture (1.5ug total protein 
(3 Units RNase H, initially)). 
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Figure 6B: Silver stained gel from SDS-PAGE analysis of 
cleavage and control samples ran in the RNase H activity gel. 
Lanes 1 and 2 contain the p66 control and cleavage sample, 
respectively. 
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Figure 6C: Autoradiogram of RNase H activity gel performed 
with p66. Lanes 1 and 2 contain E. coli RNase H (10 Units) and 






Figure 6D: Silver stained gel from SDS-PAGE analysis of the 
p66 sample used in the above activity gel. Lanes: 1, p66, 2. 
molecular weight markers. 
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aggregation or complexes of the fragments with BSA. Normally 
in SDS-PAGE, protein aggregation is not a problem because 2-
mercaptoethanol (reducing agent) is present in excess amounts 
(50mM) in the SDS-solubilization buffer. However, in the 
modified (see methods) SDS-sample buffer used in the activity 
gel assay, the concentration of 2-mercaptoethanol is 
significantly reduced (0.5mM). Furthermore, this modified 
sample buffer also contains BSA at lmg/ml, whereas the 
standard sample buffer contains no BSA. Hence the potential 
for protein aggregation is greatly increased. In order to 
show that the observed 57 and 46kDa windows were generated 
from the 51 and 42kDa fragments, respectively, the cleavage 
mixture analyzed in the above activity gel assay and a p66 
cleavage mixture in standard SDS-sample buffer (containing the 
five breakdown fragments), were Western blotted side by side 
and probed with mAb-50 (fig. 7) . As seen from the Western 
blots of these samples, the migration of the C-terminal 51 and 
42kDa bands from the standard cleavage mixture (lane 4) was 
the same as that of the two C-terminal fragments contained in 
the mixture analyzed from the activity gel analysis (lane 3) . 
Furthermore, these were the only two bands recognized by mAb-
50 in lane 3. Since the RNase H domain of p66 is associated 
with the C-terminus of the polypeptide, these results 
indicated that the two windows of RNase H activity were 
produced by the C-terminal 51 and 42kDa fragments. 
p66 and Fragment Renaturation- In order to regain enzymatic 
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Figure 7: mAb-50 probed Western blots of cleavage or control 
samples in the activity gel SDS-sample buffer or standard SDS-
sample buffer. Lanes: 1, p66 control in activity gel sample 
buffer; 2, p66 control in standard sample buffer; 3, Cleavage 
fragments in activity gel sample buffer; 4, cleavage fragments 
in standard SDS-sample buffer. 
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activity, in solution, with the SDS-denatured cleavage 
fragments (or p66), it was necessary to remove the SDS present 
in cleavage and control samples. For further analysis of the 
RNase H activity associated with the 51 and 42kDa fragments, 
attempts were made to renature these cleavage fragments in 
solution so that enzyme kinetic analysis could be performed. 
Such analysis are not possible with the activity gel assay. 
Four attempts were made to renature the fragments (or intact 
p66) following treatment with SDS in cleavage reaction 
conditions. For the first trial, after proteolysis, cleavage 
or control samples were immediately treated with guanidine 
hydrochloride (G-HC1) (see methods) and then transferred to 
dialysis tubing. The samples were then dialyzed for a total of 
41 h in renaturation buffers (see methods). In the second 
trial, samples were not treated with G-HCL. The renaturation 
procedure for the third trial was essentially identical to 
that of the second trial with the exception that PMSF was 
added to the renaturation buffer. In the fourth trial, 
immediately following PMSF termination, cleavage or control 
samples were added to ice cold, 20mg/ml BSA, prior to 
dialysis. The purpose of the BSA was to act as an alternate 
substrate for subtilisin with the view that subtilisin might 
possibly renature simultaneously with the p66 cleavage 
fragments during dialysis. In all of the above trials, after 
dialysis, aliquots of the samples were analyzed for RNase H 
activity by a liquid RNase H assay (see methods). The 
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remainder of the samples in trials one and two were 
concentrated, by ultrafiltration (see methods) and again 
analyzed for RNase H activity. Table 1 shows the results of 
the four trials. 
In the first attempt, cleavage and renaturation was 
performed with the p66/p51 HIV-RT heterodimer (see 
introduction). In contrast to procedures two, three, and four, 
guanidine hydrochloride was added prior to dialysis to ensure 
that renaturation would start from completely denatured 
(unfolded) polypeptides. However, it should be noted that 
treatment with G-HC1 resulted in the formation of precipitates 
in several steps of the renaturation procedure. Initially, 
1710 Units of RNase H (from p66/p51) were present in cleavage 
and control reactions. After dialyzing these samples to remove 
SDS and G-HC1 so that protein refolding would occur, the 
control reaction regained 25.4 Units (1.5% of total) of RNase 
H. However, there was still no detectable RNase H activity 
after identical treatment of the cleavage sample. Following a 
3-fold increase in concentration, the control contained 11.2 
units of activity (0.6% of total), whereas the cleavage sample 
still showed no detectable RNase H activity. 
In the second attempt to renature the proteins, the samples 
were not treated with G-HCl. Control and cleavage samples 
initially contained 102 Units of RNase H (from p66). After 
dialysis, 2.1 Units (2.1% of total) of RNase H was recovered 
in the control sample and no detected activity was recovered 
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Renaturation Sample Initial Units % Recovered 
Procedure Units Recovered 
1 CT 1710 25.4 1.5 
CLV 1710 0 0 
[CT] 1710 11.2 0.6 
[CLV] 1710 0 0 
2 CT 102 2.1 2.1 
CLV 102 0 0 
[CT] 102 0.2 0.2 
[CLV] 102 0 0 
3 CT 102 0 0 
CLV 102 0 0 
[CT] 102 0 0 
[CLV] 102 0 0 
4 [CT] 5.44 0.22 4.0 
[CLV] 5.44 0.07 1.3 
Table 1: Table showing RNase H activity recovered with p66 or 
p66/pbl control (CT) or cleavage reactions (CLV) after the 
dialysis renaturation procedure (see methods). 
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with the cleavage sample. After a 15-fold increase in 
concentration, the control sample contained only 0.2 Units 
(0.2% of total), while the concentrated cleavage sample still 
showed no detectable RNase H activity. Due to the lack of 
RNase H activity with the cleavage sample in this trial and 
the above trial, concentrated cleavage and control samples 
from the second trial were analyzed by SDS-PAGE to confirm 
that the fragments were still present. The results are shown 
in figure 8A. As seen from the gel, there are no cleavage 
fragments present in the concentrated cleavage sample (lane 
4). These results suggested that subtilisin may have 
reactivated, during dialysis, in the cleavage sample and 
completely degraded the fragments. 
In the third attempt to renature the proteins, PMSF was 
added to the renaturation buffer in order to insure that 
subtilisin would remain inactivated during the renaturation 
process. In the above trials, PMSF was readily removed from 
the samples by dialysis. Hence in those trials subtilisin 
could potentially have been reactivated. Once again, 102 
Units of RNase H was initially present in cleavage and control 
reactions. However, after assaying the dialyzed samples for 
RNase H activity, it was found that neither the control sample 
nor the cleavage sample contained any detectable RNase H 
activity. The lack of RNase H activity with the control sample 
could only have been due to the presence of PMSF, since the 




Figure 8A: Silver stained gel from SDS-PAGE analysis of the 
p66 control and cleavage samples used in the trial two 
renaturation experiment. Lanes: 1, p66 control prior to 
dialysis; 2, cleavage sample prior to dialysis; 3, p66 control 
after dialysis and concentration; 4, cleavage sample after 
dialysis and concentration; 5, molecular weight markers. 
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the absence of PMSF. To verify this, native (active) p66 was 
assayed for RNase H activity in the presence of PMSF and it 
was found that PMSF abolishes RNase H activity. The dialyzed 
control and cleavage samples were then analyzed by SDS-PAGE 
(fig. 8B). As expected, intact p66 was present in the control 
sample (lane 3) . However, the only bands present in the 
dialyzed cleavage sample were the 15kDa fragment and two other 
fragments with molecular masses of less than 15kDa (lane 4) . 
The fact that all five breakdown fragments were present in the 
cleavage sample, prior to dialysis (lane 2), suggests that 
even in the presence of PMSF, subtilisin is still 
significantly functional, if given sufficient reaction time 
(41 h). 
In the fourth attempt to renature p66 cleavage or control 
samples, BSA was present in the samples during dialysis in 
order to act as an alternate substrate for the reactivated 
subtilisin so as to prevent the subtilisin from completely 
degrading the fragments in the cleavage sample. Control and 
cleavage samples initially contained 5.44 Units of RNase H. 
After dialysis and concentration (see methods), 0.22 Units 
(4.0% of total) of RNase H activity was recovered in the 
control sample and 0.07 Units (1.2% of total) of RNase H 
activity was recovered in the cleavage sample. Although RNase 
H activity was observed with the cleavage sample, the specific 
source of this activity has not been determined. This activity 







Figure 8B: Silver stained gel from SDS-PAGE analysis of p66 
cleavage and control samples from the trial three renaturation 
experiment. Lanes: 1, p66 control prior to dialysis; 2, 
cleavage sample prior to dialysis; 3, p66 control after 
dialysis; 4, cleavage sample after dialysis; 5, molecular 
weight markers. 
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aggregates of these. These results, however, did indicate that 
the BSA sufficiently acted as an alternate substrate for 
subtilisin so as to protect the fragment mixture from further 
proteolytic degradation. 
Proteolysis of the 66/51 heterodimer- In order to further 
examine the proteolysis of HIV-RT, the 66/51 heterodimer was 
treated with subtilisin, in the presence of 0.95% SDS. The 
reaction time varied from 15 s to 5 min, and the cleavage 
fragments were separated by SDS-PAGE (fig. 9). In 15 s, 30 s, 
45 s, 1 min, and 2 min cleavage reactions (lanes 2-6, 
respectively), four definite breakdown fragments, which were 
not present in the 66/51 control sample (lane 1) , were 
generated. The molecular masses of these fragments were 
determined to be 42, 33, 27, and 15kDa. A 51kDa polypeptide 
was also observed in each of these samples, however, it was 
not certain whether this polypeptide was a product of 
proteolysis or if it was the initial N-terminal p51 subunit of 
the heterodimer, or both. While the intensities of the p66, 
p51 (or a 51kDa cleavage fragment), 42kDa, and 27kDa bands 
decreased with time, the intensities of the 33 and 15kDa 
cleavage bands remained constant. Hence these results were 
consistent with the p66 cleavage results, mentioned earlier. 
In order to directly compare the heterodimer cleavage 
fragments with the p66 cleavage fragments, a p66 cleavage 
sample, from a previous study, was also run on this same gel 
(lane 8). Since the migration of each of the heterodimer 
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Figure 9: Silver stained gel from SDS-PAGE analysis of limited 
proteolysis of the p66/p51 heterodimer. Proteolysis took place 
in 0.95% SDS for the indicated times. Lanes: 1, p66/p51 
control; 2, 15 s cleavage reaction; 3, 30 s cleavage reaction; 
4, 45 s cleavage reaction; 5, 1 min cleavage reaction; 6, 2 
min cleavage reaction; 7, 5 min cleavage reaction; 8, p66 
cleavage sample containing the five already described cleavage 
fragments (see figures 1A and B); 9, molecular weight markers. 
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cleavage fragments was the same as the migration of each of 
the corresponding p66 cleavage fragments, it appeared that the 
two sets of cleavage fragments were identical. 
These apparently identical sets of fragments were further 
examined by Western blot analysis. The heterodimer cleavage 
fragments and p66 cleavage fragments were transferred from the 
gel to NOP and probed with mAb-50 (fig. 10). As seen from this 
blot, mAb-50 recognized the 51 and 42kDa fragments from the 
heterodimer cleavage sample (lane 2). These C-terminal 
fragments appeared to be identical to the C-terminal 51 and 
42kDa cleavage fragments in the p66 cleavage sample (lane 3) . 
The only major band recognized by mAb-50 in the heterodimer 
control sample (lane 1) was a 66kDa band, which corresponded 
to the p66 subunit. There was a faint 51kDa band recognized by 
mAb-50 in the control sample. This polypeptide must have been 
a naturally occurring, C-terminal breakdown product, rather 
than the N-terminal p51 subunit, since the latter is missing 
the mAb-50 recognition site. 
47 
Figure 10: mAb-50 probed Western blots of cleavage or control 
samples from the p66/p51 heterodimer. Lanes: 1, p66/p51 
control; 2, cleavage fragments from heterodimer cleavage; 3, 
cleavage fragments from p66 cleavage. 
CHAPTER IV: 
DISCUSSION/CONCLUSIONS 
Limited proteolysis of p66 with subtilisin resulted in the 
production of distinct polypeptide fragments with apparent 
molecular masses of 51, 42, 33, 27, and 15 kDa. The presence 
of SDS is essential for generating these fragments. Of the 
five breakdown fragments generated, the 33 and 15kDa fragments 
appeared to be the most stable. While the intensities of the 
other fragments were significantly reduced with increasing 
reaction time, the intensities of the 33 and 15kDa fragments 
appeared to remain constant over 5 min. However, the fact that 
all of the fragments, including the 33 and 15kDa fragments, 
were completely degraded during the trial two solution 
renaturation procedure indicates that there are subtilisin 
sensitive sites on the 33 and 15kDa fragments. 
Proteolysis was more extensive in 0.095% SDS than in 0.95% 
SDS as demonstrated by complete degradation of p66 in the 70 
sec, 0.095% SDS reaction but not in the 70 s, 0.95% SDS 
reaction. Similarly the 42kDa fragment was completely degraded 
in the 5 min, 0.095% SDS reaction but not in the 5 min, 0.95% 
SDS reaction. The higher level of SDS appears to be slightly 
reducing the rate of proteolysis, such that complete 
degradation of p66 and the 42kDa fragment in these reactions 
has not occurred. This proposed rate reduction could be due 
to: (1) SDS-induced denaturing of subtilisin or (2) 
stabilization of the fragments by SDS via a change in 
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localized charge on p66, preventing recognition of the 
cleavage sites by subtilisin. It has been shown that, under 
the conditions used, no significant proteolysis occurs unless 
SDS is present. This suggests that the subtilisin sensitive 
sites of p66 are accessible only when p66 is in a denatured 
state and inaccessible when it is in the native conformation. 
Characterization of p66 proteolysis products with mAb's 
specific for defined regions of HIV-RT led to the approximate 
localization of at least two major protease sensitive sites. 
The Western blot data indicate that both these sites are 
located towards the N-terminus of p66 (fig. 11). Cleavage at 
the most N-terminal site produces the C-terminal 51 and N-
terminal 15kDa fragments, while cleavage at the other site 
produces the C-terminal 42 and N-terminal 27kDa fragments. The 
sum of the molecular masses of the 51 and 15kDa fragments is 
66kDa, the molecular mass of p66. In contrast, the sum of the 
molecular masses of the 42 and 27kDa fragments is 69kDa, 3kDa 
greater than the molecular mass of p66. However, this error 
lies within the limits of accuracy of SDS-PAGE. Since the 
51kDa fragment was recognized by both mAb-50 and mAb-42, a 
portion of the mAb-42 recognition site may overlap onto this 
fragment resulting in recognition by this mAb. The 51kDa 
fragment, however, does contain RNase H activity, confirming 
that it is a C-terminal fragment. The possibility does exist, 
however, that there may be two different 51kDa fragments, one 








Figure 11: Schematic showing the approximate location of the 
subtilisin cutting sites (arrows) of p66. 
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the 33 and 40kDa fragments were not recognized by either mAb-
50 or mAb-42, but were recognized by mAb-21, these fragments 
are probably generated from an area in the middle of p66. It 
is not known whether these fragments are generated specificly 
from intact p66 or from the 51 or the 42kDa fragment (or 
both). In other subtilisin digestions of p66 in which 
proteolysis proceeded for shorter times (10 s), all breakdown 
fragments (51, 42, 27, and 15) were produced, with the 
exception of the 33kDa fragment. This suggests that the 33kDa 
fragment may not be generated until the 51 and 42kDa fragments 
have already been produced. Therefore, it is likely that the 
51 or 42kDa fragment (or both), are precursors to the 33kDa 
fragment. 
It is unclear as to why mAb-19 failed to recognize the 27 
and 15kDa N-terminal fragments whereas, mAb-42 clearly bound 
these fragments. It has been shown that mAb-19 requires the 
first N-terminal 13 amino acids of p66 for recognition (Ferris 
et al., 1990). It is possible that during proteolysis, one or 
more of these terminal amino acids are trimmed from the N-
terminal ends of these two fragments, or from p66 prior to 
cleavage into these fragments. Another possibility is that 
binding of mAb-19 to p66 requires a conformation induced by a 
C-terminal region of p66, which is not present in the 27 or 
15kDa fragments. 
Studies involving the proteolysis of p66 have been done with 
the retroviral protease (Ferris et al., 1990) and other non 
52 
retroviral proteases (Lowe et al., 1988). In contrast to the 
above results observed with subtilisin, these groups reported 
production of an N-terminal 51kDa fragment; the corresponding 
C-terminal 15kDa fragment was not detected. Hansen et al. 
(1988) have cloned a portion of the HIV-RT gene, encoding only 
the C-terminal 15kDa region of p66, into E. coli . The 
resulting polypeptide exhibited RNase H activity when 
precipitated as an immune complex by a mAb raised against a C-
terminal portion of p66. The C-terminal 51 and 42kDa cleavage 
fragments we produced with subtilisin are unique in that they 
are large, rather than small, fragments which contain RNase H 
activity. 
It was surprising that uncleaved p66 was less active than 
the 51 and 42kDa fragments in the RNase H activity gel assay. 
In order to detect activity of p66 in this gel assay, it was 
necessary to apply 10 Units of RNase H to the gel. In 
contrast, RNase H activity of the 51 and 42kDa fragments was 
readily detected in cleavage samples which initially contained 
3 Units of RNase H. The reason for the low relative activity 
of p66 in the gel assay is not known. One possibility is that 
there may be an interaction of the reverse transcriptase 
domain of p66 with the RNase H substrate poly(rG)»poly(dC). 
This interaction could reduce RNase H activity by inducing a 
conformational change in p66 such that the RNase H domain is 
no longer functional. Loss of N-terminal regions from the 
reverse transcriptase domain by proteolysis may reduce or 
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eliminate interaction of the reverse transcriptase domain with 
the RNase H substrate, enhancing RNase H activity of the C-
terminal fragments. Another possibility may be due to faster 
renaturation of the fragments as opposed to slower 
renaturation of p66, brought about by its increase in size. A 
final possibility may be that the 51 and 42kDa fragments are 
more active than p66. Intact p66/RNase H may be under certain 
constraints induced by the N-terminal domain, whereas, these 
constraints may not be present in the C-terminal fragments. 
In the RNase H activity gel, the 51 and 42kDa fragments 
migrated with high apparent molecular weights of 57 and 46kDa, 
respectively. This altered migration may have been due to 
interaction of these fragments with the RNase H substrate in 
the gel during electrophoresis. 
In the solution renaturation experiments, RNase H activity 
was observed with p66 control samples in trials one, two, and 
four, but not with the control sample from trial three. The 
lack of RNase H activity in the control sample from trial 
three was a result of RNase H inhibition by PMSF. In trials 
one, two, and four, the RNase H activity recovered after 
dialysis of the p66 control samples was significantly less 
than the activity initially used. This decrease in RNase H 
activity may be a result of incomplete renaturation. The 
absence of RNase H activity with the cleavage samples from the 
first three renaturation trials is clearly a result of 
subtilisin reactivation and complete degradation of the 
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cleavage fragments by subtilisin. Even in the presence of PMSF 
(trial three), all of the breakdown fragments, except the 
15kDa fragment, were completely degraded. This suggests that 
either subtilisin is not completely inactivated by PMSF, or 
PMSF and SDS act together to terminate proteolysis. SDS, 
however, is removed during dialysis and thus could not aid in 
keeping subtilisin inactive. The proteolysis termination 
experiments showed that 2mM PMSF prevents subtilisin from 
degrading BSA in a 5 min reaction. However, the fact that the 
p66 cleavage fragments were completely degraded during 
renaturation in the presence of PMSF suggests that there is 
still residual subtilisin activity present. Furthermore, after 
41 h of renaturation, this residual subtilisin activity 
becomes significant. The results of the trial four solution 
renaturation procedure showed that when a large amount of BSA 
was added to the samples, RNase H activity was obtained with 
the fragment mixture, indicating that the subtilisin was no 
longer completely degrading the fragments. Although the 
recovered RNase H activity was significant, it was not high 
enough to examine by kinetic analysis. 
The breakdown products generated by the proteolysis of the 
p66/p51 heterodimer were similar, if not identical, to those 
produced by p66 proteolysis. The five major cleavage fragments 
generated from the heterodimer had the same molecular masses 
as those from the p66 cleavage. Furthermore, the 51 and 42kDa 
fragments from the heterodimer cleavage sample were recognized 
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by mAb-50, indicating that these were also C-terminal 
fragments. These results suggest that the major subtilisin 
sensitive sites of the heterodimer are contained within the 
p66 subunit and these sites are the same sites as those on the 
p66 homodimer subunits. Because of the presence of SDS (1%) in 
the proteolysis reactions, question arises to whether or not 
p66 and p66/p51 exist in the homo and heterodimer forms, 
respectively, during proteolysis. This matter has not been 
addressed. 
The data presented here show that elimination of N-terminal 
portions of the 66kDa form of HIV-RT results in C-terminal 
fragments which, under specific conditions, still contain 
RNase H activity. These fragments may help in elucidating 
mechanisms of catalysis and inhibition by RNase H specific 
inhibitors. These C-terminal fragments may also yield 
important structural information about HIV-RT. Due to the 
random ordering of HIV-RT crystals, the crystal structure of 
this enzyme has not been determined. Although a crystal 
strucure for the 15kDa, C-terminal domain has recently been 
reported (Davies et al., 1991), this polypeptide alone 
contained no detectable RNase H activity (Hostomsky et al., 
1991). In contrast, the larger C-terminal fragments described 
in this study do display RNase H activity. If these fragments 
can be crystallized, they might provide important information 
about the active conformation of RNase H, which would lead to 
the design of RNase H specific inhibitors. 
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